Survival, QOL, CV Event Rate No Better With Drug-Eluting Stents

This article originally appeared here.
Share this content:
Survival, QOL, CV Event Rate No Better With Drug-Eluting Stents
Survival, QOL, CV Event Rate No Better With Drug-Eluting Stents

WEDNESDAY, Aug. 31, 2016 (HealthDay News) -- Drug-eluting stents may perform no better for patients over the long-term, in terms of patient survival, than bare metal stents, according to a study published online Aug. 30 in the New England Journal of Medicine. The research was published to coincide with the annual European Society of Cardiology Congress, held from Aug. 27 to 31 in Rome.

Kaare Harald Bonaa, M.D., Ph.D., of the Norwegian University of Science and Technology in Trondheim, and colleagues tracked six-year outcomes for 9,013 patients. Patients received a stent after recurrent angina or a cardiovascular event such as a myocardial infarction.

Rates of revascularization procedures were low in each group: 16.5 percent in the drug-eluting stent group versus 19.8 percent in the bare-metal stent group. Patients who received a drug-eluting stent did have less need for a second revascularization procedure, but not to the level surgeons might have expected, Bonaa said. In fact, "thirty patients would need to be treated with drug-eluting stents rather than with bare-metal stents to prevent one repeat revascularization," he told HealthDay. The researchers found no significant difference between drug-eluting or bare-metal stents in either total patient deaths, nonfatal myocardial infarction, angina, or even patient quality of life.

Overall, "the take home message is that patients treated with drug-eluting stents do not live longer nor better than patients treated with bare-metal stents," Bonaa said.

Abstract
Full Text
Editorial
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

Low-Dose Hyaluronidase Can Remove Hyaluronic Acid Fillers

Low-Dose Hyaluronidase Can Remove Hyaluronic Acid Fillers

Greater resolution of nodules with hyaluronidase versus saline; more rapid resolution with higher doses

Improvement in Race-Based Disparities in Years of Life Lost

Improvement in Race-Based Disparities in Years of Life ...

Decline in race-based disparities in years of life lost seen in the United States from 1990 to 2014

Drug-Related Endocarditis Cases Up From 2007 to 2015

Drug-Related Endocarditis Cases Up From 2007 to 2015

Increase in endocarditis over nine-year study period mirrored increase in concomitant mixed drug use

is free, fast, and customized just for you!

Already a member?

Sign In Now »